Mark E. Schneiderhan, PharmD, BCPP

Bio

Dr. Schneiderhan is a Board Certified Psychiatric Pharmacist (BCPP) and Associate Professor in the department of Pharmacy Practice and Pharmaceutical Sciences at the University of Minnesota. He provides Comprehensive Medication Management (CMM) at the Human Development Center, Duluth, Minnesota, a community mental health facility serving NE Minnesota and NW Wisconsin regions. Dr. Schneiderhan has practiced in psychiatry and academia since 1994. His clinical duties include: Assessment of psychiatric and substance use disorders, Medication prescribing under collaborative practice agreement, Pharmacogenetics/pharmacokinetics consultations, and Psychopharmacy consultative services to primary care providers. He provides education specializing in schizophrenia, mood disorders, anxiety disorders, behavioral dyscontrol, and substance use disorders for pharmacy students.

Expertise

Management of symptoms of Schizophrenia, Major Depressive Disorders, Bipolar Disorders, Anxiety disorders, OCD and PTSD, Behavioral dyscontrol disorders, and Substance use disorders

Awards & Recognition

• University of Minnesota Academy for Excellence in Clinical Practice 2020 Inductee - This award serves as the highest recognition of excellence in the practice or provision of clinical care by a full-time faculty member.

Professional Associations

American Association of Psychiatric Pharmacists - AAPP (formerly: College of Psychiatric and Neurologic Pharmacists (CPNP) www.cpnp.org

American College of Clinical Pharmacists (ACCP)

American Association of Colleges of Pharmacy (AACP)

Minnesota Pharmacist Association, Professional Affairs

Research Summary

Metabolic-risk among patients with serious mental illness and concurrent antipsychotic therapy

Clinical

Specialties

• Psychiatry

Clinics

Human Development Center

Bishop JR, Schneiderhan ME, Butler T, Carpentier RM, Heins KR, Formea CM. Pharmacogenomics to support mental health medication therapy management: Clinical practice considerations and a conceptual framework to enhance patient care. J Am Coll Clin Pharm. 2024;7(2):160‐170. doi:10.1002/jac5.1892

Schneiderhan ME, O'Donnell C, Jackson SK, MacDonald DA, Yapel AM, Renier CM, Albee JN, Hager KD. Bridging Community Mental Health and Primary Care to Improve Medication Monitoring and Outcomes for Patients With Mental Illness Taking Second-Generation Antipsychotics-Phase 2: Quality Improvement Initiative Over 15 Months. Prim Care Companion CNS Disord. 2023 Jun 27;25(3):22m03432. doi: 10.4088/PCC.22m03432. PMID: 37419461.

Schneiderhan, M. E., Nelson, L. A., Bishop, J. R., & Bauer, S. (2022). Evaluation of Psychiatric Illness. Pharmacotherapy: A Pathophysiological Approach 12th ed.. New York: The McGraw-Hill Company, Inc. https://a.co/d/7s7a38B

Schneiderhan, M. E. & Li, X. Observed sex differences in cardiometabolic indices in patients on antipsychotics: Secondary analyses of a 12 month, multicenter, randomized controlled trial. The Primary Care Companion for CNS Disorders 2021 Apr 8;23(2):19m02493. doi: 10.4088/PCC.19m02493. PMID: 34000112.

Schneiderhan ME, Nelson L, Bishop JR, Bauer S. Evaluation of Psychiatric Illness. In: DiPiro JT, Yee GC, Michael Posey LL, Haines ST, Nolin TD, Ellingrod VL. eds. DiPiro: Pharmacotherapy A Pathophysiologic Approach, 12e. McGraw Hill; 2021. Accessed February 22, 2022. https://accesspharmacy-mhmedical-com.ezp1.lib.umn.edu/content.aspx?bookid=3097§ionid=264560590 

Brown JT, Bishop JR, Schneiderhan ME. Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management. Ment Health Clin. 2020;10(4):254-258. Published 2020 Jul 2. doi:10.9740/mhc.2020.07.254

Okoro ON, Bastianelli KM, Wen Y, Bilden E, Konowalchuk BK, Schneiderhan ME. Awareness of state legislation on naloxone accessibility associated with willingness to prescribe naloxone. Subst Abuse 2017;online;1-5. http://www.tandfonline.com/doi/full/10.1080/08897077.2017.1356787 

Brown JT, Schneiderhan ME, Eum S, Bishop JR. “Serum clomipramine and desmethlyclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.” Pharmacogenomics 2017;18(7): https://www-futuremedicine-com.ezp3.lib.umn.edu/doi/10.2217/pgs-2017-0015

Schneiderhan ME, Eum S, Brown JT, Bishop JR. “Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report” BMC Psychiatry 2017;17:238: https://www-ncbi-nlm-nih-gov.ezp1.lib.umn.edu/pmc/articles/PMC5496345/ 

Schneiderhan ME, Nelson, Leigh A., Bauer, S. “Assessment of Psychiatric Disorders.” In: DiPiro, Talbert, Yee, Matzke, Wells, Posey. eds. Pharmacotherapy: A Pathophysiological Approach, Tenth Edition. The McGraw-Hill Company, Inc. (eChapter62) 2017. http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861§ionid=146079284 

Schneiderhan ME, Shuster S, Davey CS. “12-month prospective randomized study of pharmacists utilizing point-of-care screenings for metabolic syndrome and related conditions in subjects prescribed antipsychotics.” Prim Care Companion CNS Disord 2014;16(5): (http://www.psychiatrist.com/PCC/article/Pages/2014/v16n05/14m01669.aspx)

Schneiderhan ME. Two Case Reports of Smoking Behavior Changes After Self-initiated E-cigarette Use and Tobacco Smoking Cessation. Ment Health Clin. 2012;2(6):26. Available at: http://cpnp.org/resource/mhc/2012/12/two-case-reports-smoking-behavior-changes-after-self-initiated-e-cigarette-use. Accessed March 7, 2013.

Batscha C, Schneiderhan ME, Kataria Y, Rosen C, Marvin R. "Treatment settings and metabolic monitoring for people experiencing first-episode psychosis." J Psychosoc Nur Ment Health Serv 2010;48(9):44-49. Schneiderhan ME, Batscha C, Rosen C. “Assessment of a Point-of-Care Metabolic Risk Screening Program in Outpatients Receiving Antipsychotic Agents.” Pharmacotherapy 2009;29(8):975-987.

Schneiderhan ME, Marvin R. “Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain.” Am J Ther 2007;14:581–584.

Kaplan KJ, Schneiderhan ME, Harrow M, Omens R. “Autonomy, Gender, and Preference for Paternalistic or Informative Physicians: A Study of the Doctor-Patient Relation.” Ethics & Medicine 2002;18(1):49-60.

Kaplan KJ, Harrow M, Schneiderhan ME. “Suicide, Physician-Assisted Suicide and Euthanasia in Men versus Women around the world: The Degree of Physician Control.” Ethics & Medicine, 2002;18(1):33-48.

Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL. “Attenuation of antipsychotic-induced hyperprolactinemia with clozapine.” J Child Adolesc Psychopharmacol 1997;7(1):65-69.

Littrell RA, Schneiderhan M, “The Neurobiology of Schizophrenia.” Pharmacotherapy 1996;16(6):143s-147s; Discussion 166s-168s

Schneiderhan ME, Gross AG, Marken PA; Ruehter VL, Schmidt SL. “Conversion from oral to i.m. fluphenazine is not a simple matter.” Am J Health Syst Pharm 1995 Dec 15:52(24):2826-7.

Schneiderhan ME, Marken PA. “An atypical course of neuroleptic malignant syndrome.” J Clin Pharmacol. 1994;34(4):325-334. Schneiderhan ME. “Is vitamin E effective in the treatment of tardive dyskinesia?” Ann Pharmacother. 1993;27(3):311-312.

"Retrospective review of clinical outcome measures in patients receiving comprehensive medication management pharmacist services in a community mental health setting." PI: Mark E. Schneiderhan, PharmD, BCPP IRB #STUDY00002090. 2/19/2018-10/19/2022 UMN-COP Internal Grants: Enhance Comprehensive Pharmacist Services to Improve Patient Health Clinical Research Award and Academy for Excellence in Clinical Practice Award. Clinical Site: Human Development Center. Grant Period: 11/1/17 – 10/19/2023.

Interview describing my role as faculty and clinician in psychiatric pharmacy - 09/23/2021